Where are they now?

Mar 01, 2002

Premium

A year ago this month, GT looked at Genaissance Pharmaceuticals and its direct competitor, Variagenics. At the time, Genaissance posited that its gamble on finding haplotypes would pay off in the sale of pharmacogenomic information. Variagenics, meanwhile, pursued its proprietary genotyping technology as the path to riches.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Warren Releases Genetic Ancestry Results

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Thirty-One Recommended for Removal

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz Dies

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

This Week in PLOS

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.

Main menu